Abstract:Background: The third fatal coronavirus is the novel coronavirus (SARS-CoV-2) that causes novel coronavirus pneumonia (COVID-19) which first broke out in December 2019. Patients will develop rapidly if there is no any intervention, so the risk identification of severe patients is critical. The aim of this study was to investigate the characteristics and rules of hematology changes in patients with COVID-19, and to explore the possibility differentiating moderate and severe patients using conventional hematology parameters or combined parameters. Methods: The clinical data of 45 moderate and severe type patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections in Jingzhou Central Hospital from January 23 to February 13, 2020 were collected. The epidemiological indexes, clinical symptoms, and laboratory test results of the patients were retrospectively analyzed. Those parameters with significant differences between moderate and severe cases were analyzed, and the combination parameters with the best diagnostic performance were selected using the linear discriminant analysis (LDA) method. Results: Of the 45 patients with the novel 2019 corona virus (COVID-19) (35 moderate and 10 severe cases), 23 were male and 22 were female, with ages ranging from 16 to 62 years. The most common clinical symptoms were fever (89%) and dry cough (60%). As the disease progressed, white blood cell count (WBC), neutrophil count, neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), red blood cell distribution width-coefficient of variation (RDW-CV), and red cell volume distribution width-standard deviation (RDW-SD) parameters in the severe group were significantly higher than those in the moderate group (P<0.05); meanwhile, lymphocyte count (Lym#), eosinophil count (Eos#), high fluorescent cell percentage (HFC%), red blood cell count (RBC), hemoglobin (HGB), and hematocrit (HCT) parameters in the severe group were significantly lower than those in the moderate group (P<0.05). For NLR parameter, it's area under the curve (AUC), cutoff, sensitivity and specificity were 0.890, 13.39, 83.3% and 82.4% respectively; meanwhile, for PLR parameter, it's AUC, cutoff, sensitivity and specificity were 0.842, 267.03, 83.3% and 74.0% respectively. The combined parameters of NLR and RDW-SD had the best diagnostic efficiency (AUC =0.938), and when the cutoff value was 1.046, the sensitivity and the specificity were 90.0% and 84.7% respectively, followed by the combined parameter NLR&RDW-CV (AUC =0.923). When the cut-off value was 0.62, the sensitivity and the specificity for distinguishing severe type from moderate cases of COVID-19 were 90.0% and 82.4% respectively. Conclusions: The combined NLR and RDW-SD parameter is the best hematology index. It may help clinicians to predict the severity of COVID-19 patients and can be used as a useful indicator to help prevent and control the epidemic.

Identification of parameters in routine blood and coagulation tests related to the severity of COVID-19

Prediction of Severe Illness Due to COVID-19 Based on an Analysis of Initial Fibrinogen to Albumin Ratio and Platelet Count.

Serum IL-6 and Procalcitonin Are Two Promising Novel Biomarkers for Evaluating the Severity of COVID-19 Patients.

IP-10 and MCP-1 As Biomarkers Predicting Disease Severity of COVID-19

Diagnostic utility of clinical laboratory data determinations for patients with the severe COVID‐19

Analysis of Blood Index Characteristics in COVID-19 Patients and Their Associations with Different Outcomes

Prognostic value of interleukin-6, C-reactive protein, and procalcitonin in patients with COVID-19

Correlation analysis between disease severity and clinical and biochemical characteristics of 143 cases of COVID-19 in Wuhan, China: a descriptive study

Clinical value of blood markers to assess the severity of coronavirus disease 2019

Analysis of Dynamic Disturbance in Blood Coagulation Function of Patients with Coronavirus Disease 2019: A Retrospective Observational Study.

Early coagulation tests predict risk stratification and prognosis of COVID-19

Clinical value of laboratory indicators for predicting disease progression and death in patients with COVID-19: a retrospective cohort study

Prediction of Clinical Severity of COVID‐19 Using a Combination of Heparin‐Binding Protein, Interleukin‐6, and C‐Reactive Protein: A Retrospective Study

Dynamic changes in coagulation parameters and correlation with disease severity and mortality in patients with COVID-19

Analysis of dynamic disturbance in blood coagulation function of 261 patients with Coronavirus Disease 2019

Correlation analysis between disease severity and inflammation-related parameters in patients with COVID-19: a retrospective study

Preliminary study to identify severe from moderate cases of COVID-19 using combined hematology parameters

Analysis of coagulation parameters in patients with COVID-19 in Shanghai, China.

A Retrospective Study of the C-Reactive Protein to Lymphocyte Ratio and Disease Severity in 108 Patients with Early COVID-19 Pneumonia from January to March 2020 in Wuhan, China

Meta-Analysis of D-Dimer, hsCRP and Cytokines in COVID-19 Severe/Critical Patients in China

Potential Factors for Prediction of Disease Severity of COVID-19 Patients